Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

87.22USD
11 Dec 2018
Change (% chg)

-- (--)
Prev Close
$87.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,287,429
52-wk High
$94.19
52-wk Low
$72.30

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 0.75
Market Cap(Mil.): $225,092.70
Shares Outstanding(Mil.): 2,550.62
Dividend: 2.94
Yield (%): 3.06

Financials

  NVS Industry Sector
P/E (TTM): 15.65 29.45 30.88
EPS (TTM): 5.68 -- --
ROI: 11.90 14.34 13.80
ROE: 17.75 15.85 15.29

Swiss stocks - Factors to watch on Dec. 11

ZURICH/BERLIN, Dec 11 The Swiss blue-chip SMI was seen opening 1.0 percent higher at 8,634 points on Tuesday, according to premarket indications by bank Julius Baer .

Dec 11 2018

Novartis to launch Adamis' EpiPen rival in U.S. next year

Dec 6 Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products.

Dec 06 2018

J&J unit to pay $360 million to U.S. to resolve charity kickback probe

BOSTON A Johnson & Johnson unit will pay the U.S. government $360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the Justice Department said on Thursday.

Dec 06 2018

UPDATE 3-J&J unit to pay $360 mln to U.S. to resolve charity kickback probe

BOSTON, Dec 6 A Johnson & Johnson unit will pay the U.S. government $360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the Justice Department said on Thursday.

Dec 06 2018

BRIEF-Qiagen Announces New Collaboration With Novartis

* QIAGEN ANNOUNCES NEW COLLABORATION TO DEVELOP COMPANION DIAGNOSTIC TO GUIDE TREATMENT FOR PATIENTS WITH PIK3CA-MUTATED ADVANCED BREAST CANCER

Dec 06 2018

J&J unit to pay $360 mln to U.S. to resolve charity kickback probe

BOSTON, Dec 6 A unit of Johnson & Johnson has agreed to pay the U.S. government $360 million to resolve an investigation into its financial support of charities that help Medicare patients cover out-of-pocket drug costs, the U.S. Justice Department said on Thursday.

Dec 06 2018

BRIEF-Novartis Says BYL719 Improved PFS In Patients With A Type of Breast Cancer

* NOVARTIS INVESTIGATIONAL BYL719 (ALPELISIB) PLUS FULVESTRANT CONSISTENTLY IMPROVED PFS IN PATIENTS WITH PIK3CA MUTATED HR+/HER2- ADVANCED BREAST CANCER IN NEW SOLAR-1 ANALYSES Source text for Eikon: [https://bit.ly/2E3vBMV]

Dec 06 2018

BRIEF-Intellia Therapeutics And Novartis Expand Cell Therapy Collaboration

* INTELLIA THERAPEUTICS AND NOVARTIS EXPAND CELL THERAPY COLLABORATION TO PURSUE CRISPR/CAS9-BASED GENOME EDITING IN ADDITIONAL STEM CELL POPULATION

Dec 06 2018

Novartis's new treatment for hives outperforms Xolair in trials

ZURICH Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives.

Dec 04 2018

UPDATE 1-Novartis's new treatment for hives outperforms Xolair in trials

ZURICH, Dec 4 Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives.

Dec 04 2018

Earnings vs. Estimates